Latest & greatest articles for albuterol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on albuterol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on albuterol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for albuterol

1. Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial. (Abstract)

Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial. In moderate-severe asthma exacerbation, salbutamol by inhaler (MDI) is superior to salbutamol delivered by nebulizer (NEB); however, to our knowledge, no studies in children with exclusively severe exacerbations were performed.To compare the efficacy of salbutamol and ipratropium bromide by MDI versus by NEB in severe asthma exacerbations.We performed (...) a clinical trial enrolling 103 children (2-14 years of age) with severe asthma exacerbations (defined by the Pulmonary Score ≥ 7) seen at the emergency room in Asuncion, Paraguay. One group received salbutamol and ipratropium (two puff every 10 min for 2 h and then every 30 min for 2 h more) by MDI with a valved-holding chamber and mask along with oxygen by a cannula separately (MDI-SIB); and the other received nebulization with oxygen (NEB-SIB) of salbutamol and ipratropium (1 every 20 min for 2 h

2019 Pediatric pulmonology Controlled trial quality: uncertain

2. [Comparison by double-blind study of the combination of an aerosol of salbutamol and ipratropium bromide and its individual effect in chronic bronchitis and bronchial asthma]. (Abstract)

Moreno R R Luque Leal J J Palacios Giner A A spa Clinical Trial Comparative Study English Abstract Journal Article Randomized Controlled Trial Comparación en estudio doble ciego de la asociación de un aerosol de salbutamol y bromuro de ipratropio y de su efecto individual en bronquitis crónica y asma bronquial. Spain Rev Clin Esp 8608576 0014-2565 0 Aerosols 0 Atropine Derivatives GR88G0I6UL Ipratropium QF8SVZ843E Albuterol IM Aerosols Albuterol administration & dosage Asthma drug therapy Atropine (...) [Comparison by double-blind study of the combination of an aerosol of salbutamol and ipratropium bromide and its individual effect in chronic bronchitis and bronchial asthma]. 6229844 1984 03 22 2013 11 21 0014-2565 171 4 1983 Nov 30 Revista clinica espanola Rev Clin Esp [Comparison by double-blind study of the combination of an aerosol of salbutamol and ipratropium bromide and its individual effect in chronic bronchitis and bronchial asthma]. 265-8 Baños Hidalgo P P Ramos Martos A A Cabrera

1984 Revista Clinica Espanola Controlled trial quality: uncertain

3. Albuterol

have questions please contact us via jon.brassey@tripdatabase.com Top results for albuterol 1. Clinical comparison of fenoterol and albuterol administered by inhalation. A double-blind study. 344007 1978 05 17 1978 05 17 2013 11 21 0012-3692 73 3 1978 Mar Chest Chest Clinical comparison of fenoterol and albuterol administered by inhalation. A double-blind study. 348-51 The effects of inhaling 0.4 mg of fenoterol hydrobromide (Berotec), 0.2 mg of albuterol (salbutamol), or placebo were compared (...) of Cardiogenic Pulmonary Edema. Congestive Heart Failure Drug: Albuterol Drug: Normal Saline Phase 2 Phase 3 Study Type: Interventional 2010 8. A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol /Salbutamol and Ipratropium A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol /Salbutamol and Ipratropium - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles

2018 Trip Latest and Greatest

4. A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01656811 Recruitment Status : Completed First Posted : August 3, 2012 Last Update

2012 Clinical Trials

5. Safety Study of Albuterol Spiromax® in Subjects With Asthma

Safety Study of Albuterol Spiromax® in Subjects With Asthma Safety Study of Albuterol Spiromax® in Subjects With Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety Study of Albuterol Spiromax® (...) ): Teva Pharmaceutical Industries Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety of Albuterol Spiromax® over 52 weeks during two dosing periods: (1) a 12-week, double-blind, placebo-controlled QID dosing period followed by (2) a 40-week, open-label PRN dosing period, and to evaluate Albuterol Spiromax® device performance through the life of the device during the study. Condition or disease Intervention/treatment Phase Asthma Drug: Placebo MDPI

2012 Clinical Trials

6. Salbutamol Administration via Nebulizer Versus Metered-Dose Inhalers: Clinical Effectiveness and Cost-Effectiveness

Salbutamol Administration via Nebulizer Versus Metered-Dose Inhalers: Clinical Effectiveness and Cost-Effectiveness Salbutamol Administration via Nebulizer Versus Metered-Dose Inhalers: Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Salbutamol Administration via Nebulizer Versus Metered-Dose Inhalers: Clinical Effectiveness and Cost-Effectiveness Salbutamol Administration via Nebulizer Versus Metered-Dose Inhalers: Clinical Effectiveness and Cost (...) -Effectiveness Last updated: August 2, 2019 Project Number: RB1367-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of administering salbutamol via nebulizer versus metered dose inhalers in pre-hospital or emergency settings? What is the cost-effectiveness of administering salbutamol via nebulizer versus metered dose inhalers in pre-hospital or emergency settings? Key Message One randomized controlled trial and one non

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. [Nocturnal asthma: inhalation treatment with high doses of salbutamol and beclomethasone]. (Abstract)

[Nocturnal asthma: inhalation treatment with high doses of salbutamol and beclomethasone]. 3738002 1986 09 16 2013 11 21 0014-2565 178 7 1986 Apr Revista clinica espanola Rev Clin Esp [Nocturnal asthma: inhalation treatment with high doses of salbutamol and beclomethasone]. 322-6 Rodríguez Sanchón B B Manresa F F Romero P P Cardona M J MJ spa Clinical Trial English Abstract Journal Article Randomized Controlled Trial Asma nocturno: tratamiento con dosis altas de salbutamol y beclometasona por (...) vía inhalatoria. Spain Rev Clin Esp 8608576 0014-2565 KGZ1SLC28Z Beclomethasone QF8SVZ843E Albuterol IM Adult Albuterol administration & dosage Asthma drug therapy physiopathology Beclomethasone administration & dosage Circadian Rhythm Drug Therapy, Combination Female Humans Male Middle Aged Prospective Studies Respiratory Therapy 1986 4 1 1986 4 1 0 1 1986 4 1 0 0 ppublish 3738002

1986 Revista Clinica Espanola Controlled trial quality: uncertain

8. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. Full Text available with Trip Pro

Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. Many patients with asthma require frequent rescue medication for acute symptoms despite appropriate controller therapies. Thus, determining the most effective relief regimen is important in the management of more severe asthma. This study's objective was to evaluate whether ipratropium bromide/albuterol metered-dose inhaler (CVT-MDI) provides (...) more effective acute relief of bronchospasm in moderate-to-severe asthma than albuterol hydrofluoroalkaline (ALB-HFA) alone after 4 weeks.In this double-blind, crossover study, patients who had been diagnosed with asthma for ≥1 year were randomized to two sequences of study medication "as needed" for symptom relief (1-7 day washout before second 4-week treatment period): CVT-MDI/ALB-HFA or ALB-HFA/CVT-MDI. On days 1 and 29 of each sequence, 6-hour serial spirometry was performed after

2016 BMC pulmonary medicine Controlled trial quality: predicted high

9. RANDOMISED DOUBLE BLIND STUDY TO COMPARE EFFECTIVENESS OF HONEY, SALBUTAMOL AND PLACEBO IN TREATMENT OF COUGH IN CHILDREN WITH COMMON COLD. (Abstract)

RANDOMISED DOUBLE BLIND STUDY TO COMPARE EFFECTIVENESS OF HONEY, SALBUTAMOL AND PLACEBO IN TREATMENT OF COUGH IN CHILDREN WITH COMMON COLD. Acute upper respiratory infection is the most common childhood illness and presents with cough, coryza and fever. Available evidence suggests that cough medicines may be no more effective than honey-based cough remedies.To compare effectiveness of honey, salbutamol and placebo in the treatment of cough in children with acute onset cough.Randomised control (...) trial.Aga Khan University Hospital Paediatric Casualty.Children between ages one to twelve years presenting with a common cold between December 2010 and February 2012 were enrolled.Frequency, severity and extent to which cough bothered and disturbed child and parental sleep were assessed at baseline and over the subsequent five days through telephone interview using a validated scoring tool.One hundred and forty five children were enrolled in the study (45- placebo, 57 -honey, 43 -salbutamol

2016 East African medical journal Controlled trial quality: predicted high

10. Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. (Abstract)

Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. To compare the efficacy of nebulised salbutamol alone and in combination with ipratropium bromide in acute severe asthma in children.The randomised controlled trial was conducted at the National Institute of Child Health, Karachi, from October 2012 to March 2013, and comprised patients with acute severe asthma who were randomised into two equal groups. Group A patients received 3 (...) doses of nebulised salbutamol alone (0.03 ml/kg/dose) at 15-minute intervals and Group B received 3 similar doses of salbutamol along with ipratropium (250 ug/dose). Acute severe asthma was categorised as serve exacerbation (clinical score >10) and moderate (5-10 score) based on Bentur Modification. Efficacy was measured after 5minutes of the last dose by change in severity score from severe exacerbation (baseline) to low score. SPSS 10 was used for statistical analysis.There were two groups of 100

2016 JPMA. The Journal of the Pakistan Medical Association Controlled trial quality: uncertain

11. Acute effects of salbutamol on systemic vascular function in people with asthma. (Abstract)

Acute effects of salbutamol on systemic vascular function in people with asthma. Asthmatics are at increased cardiovascular disease risk, which has been linked to beta2(β2)-agonist use. Inhalation of β2-agonists increases sympathetic nerve activity (SNA) in healthy individuals, however the systemic impact of salbutamol in asthmatics using β2-agonists regularly is unknown.This study compared the systemic vascular responses to a clinical dose of salbutamol (Phase I) and following an acute (...) increase in SNA (Phase II) in asthmatics and controls.Fourteen controls and 14 asthmatics were recruited for Phase I. On separate days, flow-mediated dilation (FMD) and peripheral arterial stiffness (pPWV) were evaluated at baseline and following either 400 μg inhaled salbutamol or a placebo inhaler. For Phase II, heart rate, blood pressure, vascular conductance, pPWV, and central (c)PWV were evaluated in response to a large increase in SNA brought on by cold-water hand immersion (i.e. cold-pressor

2019 Respiratory medicine Controlled trial quality: uncertain

12. Asthma admission rates and patterns of salbutamol and inhaled corticosteroid prescribing in England from 2013 to 2017. (Abstract)

Asthma admission rates and patterns of salbutamol and inhaled corticosteroid prescribing in England from 2013 to 2017. Asthma exacerbations are a common reason for hospital admission. We sought to identify whether patterns of inhaler prescribing are significantly associated with regional asthma admission rates. Asthma admission rates were obtained for English Clinical Commissioning Group (CCG) regions from 2013/2014 to 2016/2017. Raw prescribing data were obtained from OpenPrescribing.net (...) , based on monthly general practice-level data published by the National Health Service Business Services Authority. Data were analysed using a linear mixed effects model. The ratio of salbutamol to inhaled corticosteroid prescriptions within a CCG was positively associated with asthma admission rates, independently of median age, asthma prevalence and socioeconomic deprivation.© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

2019 Thorax

13. A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (MANDALA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated

2018 Clinical Trials

14. Albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane versus placebo in children with persistent asthma. (Abstract)

Albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane versus placebo in children with persistent asthma. Many children struggle with albuterol hydrofluoroalkane (HFA) inhalers. Albuterol multidose dry powder inhaler (MDPI) may simplify rescue bronchodilator use in children.To demonstrate the comparability of albuterol MDPI and albuterol HFA in children with asthma.This phase II, multicenter, double-blind, double-dummy, single-dose, five-period, crossover study randomized (...) patients (ages 4-11 years) with persistent asthma and prestudy forced expiratory volume in 1 second (FEV1) of 60-90% of predicted to 1 of 10 treatment sequences that contained albuterol MDPI (90 and 180 μg), albuterol HFA (90 and 180 μg), and placebo MDPI and placebo HFA. Efficacy was evaluated by measuring the area under the baseline-adjusted percent-predicted FEV1-time curve over 6 hours (PPFEV1 AUC0-6) after dosing. Safety was evaluated by adverse events.The full analysis set included 61 patients

2016 Allergy and Asthma Proceedings Controlled trial quality: predicted high

15. Is nebulised salbutamol indicated in bronchiolitis?

of nebulised salbutamol in patients with bronchiolitis. References Schuh S, Canny G, Reismann JJ, Kerem E, Bentur L, Petric M, Levison H. Nebulised albuterol in acute bronchiolitis. Journal of Pediatrics. 1990;117(4):633-637. Klassen TP, Rowe PC, Sutcliffe T, Ropp LJ, McDowell IW, Li MM. Randomised trial of salbutamol in acute bronchiolitis. The Journal of Pediatrics. 1991;118(5):807-811. Gadomski AM, Aref GH, EL Din OB, EL Sawy IH, Khallaf N, Black RE. Oral versus nebulised albuterol in the management (...) of bronchiolitis. Singapore Medical Journal. 1997;38(8):326-328. Dobson JV, Stephen -Groff SM, McMahon SR, Stemmler MM, Brallier SL, Bay C. The use of albuterol in hospitalised infants with bronchiolitis. Pediatrics. 1998;101(3 Pt 1):361-368. Ho L, Collis G, Landau LI, Le Souf PN. Effect of salbutamol on oxygen saturation in bronchiolitis. Archives of Disease in Childhood. 1991;66(9):1061-1064. Wang EE, Milner R, Allen U, Maj H. Bronchodilators for treatment of mild bronchiolitis : a factorial randomised trial

2009 BestBETS

16. Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. (Abstract)

Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. This study aimed to investigate the dose-response and pharmacology of a range of single doses of nebulised ensifentrine (RPL554), an inhaled dual phosphodiesterase (PDE) 3/4 inhibitor in patients with asthma.In this randomised, placebo-controlled, double-blind crossover study, patients received single nebulised doses of ensifentrine 0.4, 1.5, 6 and 24 mg, salbutamol 2.5 and 7.5 mg (...) , and placebo. Eligible patients were adults with asthma, pre-bronchodilator forced expiratory volume in 1 s (FEV1) 60-90% predicted and ≥1.5 L, with post-salbutamol FEV1 increase ≥15%. The co-primary objectives were peak and average FEV1 over 12 h for ensifentrine vs placebo and salbutamol. Secondary endpoints included: peak and average systolic and diastolic blood pressure, pulse rate and ECG heart rate; and safety and tolerability (adverse events [AEs], and serum potassium). ClinicalTrials.gov

2019 Pulmonary Pharmacology & Therapeutics Controlled trial quality: predicted high

17. Effects of a PICU Status Asthmaticus De-Escalation Pathway on Length of Stay and Albuterol Use. (Abstract)

Effects of a PICU Status Asthmaticus De-Escalation Pathway on Length of Stay and Albuterol Use. Evaluate the effects of an asthma de-escalation clinical pathway on selected outcomes for patients admitted to a PICU with status asthmaticus.Time series quality improvement trial.PICU in a tertiary care children's hospital.Children age 2-18 years old with a known diagnosis of asthma presenting with status asthmaticus.One-hundred five admissions to a PICU for status asthmaticus were treated according (...) to a new de-escalation pathway between August 15, 2015, and August 30, 2016. This group was compared with a prepathway group of 141.Primary outcome was variability in PICU length of stay. Secondary outcomes were median PICU length of stay, median hospital length of stay, and median duration a patient received continuous nebulized albuterol. The effectiveness of the intervention was tracked using control charts. The postpathway group demonstrated decreased variability of PICU length of stay and time

2018 Pediatric Critical Care Medicine

18. Is Transcellular Potassium Shifting With Insulin, Albuterol, or Sodium Bicarbonate in Emergency Department Patients With Hyperkalemia Associated With Recurrent Hyperkalemia After Dialysis? (Abstract)

Is Transcellular Potassium Shifting With Insulin, Albuterol, or Sodium Bicarbonate in Emergency Department Patients With Hyperkalemia Associated With Recurrent Hyperkalemia After Dialysis? Emergency department (ED) treatment of hyperkalemia often involves shifting potassium into the intracellular space. There is uncertainty whether transcellular shifting causes insufficient potassium removal during hemodialysis, resulting in a subsequent need for further medical therapy or multiple sessions (...) of hemodialysis.We sought to determine whether transcellular potassium shifting in ED patients with hyperkalemia who undergo hemodialysis is associated with recurrent hyperkalemia with or without repeat hemodialysis within 24 h.This was a retrospective observational study of ED patients with a potassium value > 5.3 mmol/L and ≥1 hemodialysis run. Transcellular shifting medications were defined as albuterol, insulin, and sodium bicarbonate. Primary outcomes were recurrent hyperkalemia with and without repeat

2018 Journal of Emergency Medicine

19. Takotsubo cardiomyopathy with use of salbutamol nebulisation and aminophylline infusion in a patient with acute asthma exacerbation Full Text available with Trip Pro

Takotsubo cardiomyopathy with use of salbutamol nebulisation and aminophylline infusion in a patient with acute asthma exacerbation Takotsubo cardiomyopathy, apical ballooning syndrome or stress-induced cardiomyopathy is characterised by transient left ventricular dysfunction, mimicking myocardial infarction in the absence of obstructive coronary artery disease or acute plaque rupture on coronary angiography. The exact mechanism of myocardial dysfunction in Takotsubo cardiomyopathy is unknown

2016 BMJ case reports

20. Bronchopulmonary pharmacokinetics of (R)‐salbutamol and (S)‐salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses Full Text available with Trip Pro

Bronchopulmonary pharmacokinetics of (R)‐salbutamol and (S)‐salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses Salbutamol is usually administered as a racemic mixture but little is known about the enantioselectivity of salbutamol pharmacokinetics in the lung. This study was designed to investigate enantiomer concentrations in lung tissue after inhaled dosing.Horses (n = 12) received racemic salbutamol 1000 μg via inhalation. Enantioselective ultra (...) performance liquid chromatography-tandem mass spectrometry was used to determine salbutamol concentrations in pulmonary epithelial lining fluid (PELF) sampled 2, 5, 10 and 15 min after administration, in central lung (endoscopic bronchial biopsy) and peripheral lung (percutaneous pulmonary biopsy) tissues (at 20 and 25 min respectively), and in plasma samples.Mean ± 95% confidence interval (CI) yield of PELF was 57 ± 10 mg. Initial mean ± 95%CI (R)- and (S)-salbutamol PELF concentrations were 389 ± 189 ng

2017 British journal of clinical pharmacology